FDA publishes new guidance to promote innovation in general wellness and clinical decision support, impacting medical AI including radiology.
Key Details
- 1FDA released updated guidance for general wellness products and clinical decision support (CDS) software.
- 2New guidelines aim to reduce regulatory confusion and encourage rapid AI innovation in healthcare devices.
- 3Commissioner Makary said FDA wants to 'promote more innovation with AI and medical devices.'
- 4Hospital OSF HealthCare developed 'CliniPane,' an in-house AI platform for care team notification based on patient deterioration.
- 5Anthropic launched Claude for Healthcare, a HIPAA-compliant medical LLM, challenging ChatGPT.
- 6Radiology-specific mention: Aidoc named a former AMA president as chief medical officer.
Why It Matters
Clearer regulatory direction for AI-driven CDS products, including radiology tools, may accelerate deployment, reduce compliance worries, and foster innovation. Hospital in-house AI and new medical LLM entrants signal potent competition and rapid evolution in imaging and clinical AI.
Source
HealthExec
Related News
•Radiology Business
NCCN Endorses AI Risk Tools for Breast Cancer Screening
NCCN's 2026 guidelines recommend routine integration of AI-based 5-year breast cancer risk prediction from mammograms.
•Radiology Business
ACR Expands Resources for Radiology Practices to Assess Imaging AI
The ACR is offering new tools to help radiology practices evaluate and monitor imaging AI algorithms.
•AuntMinnie
FDA Rejects Petition to Exempt Radiology AI Devices from 510(k) Review
FDA denies a petition to exempt certain radiology AI software from 510(k) review, stressing ongoing regulatory oversight.